Lab study tests antibody that could unlock immune attack on liver cancer

NCT ID NCT02868255

Completed Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at a new antibody called anti-SIRPα as a potential immunotherapy for liver cancer. Researchers used blood and tissue samples from 30 liver cancer patients to see how the antibody affects immune cells. The goal was to understand whether blocking the SIRP-CD47 pathway could help the immune system fight cancer. This was a lab-based study, not a treatment trial, so no patients received the antibody.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-SIRPα antibody
What this could lead to: If this approach works, it could point toward a new immunotherapy for liver and ovarian cancers.
What could go wrong: This was a very early lab study using patient samples, not a treatment trial. The antibody has not yet been tested in people, so it may not work or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

CHU de Nantes

Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.